Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0278080 (physical dependence)
 1,658 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The biological mechanisms examined in this paper cover only a small portion of those that may be involved in the pathogenesis of alcoholism. Certain areas on which a great deal of work has already been done have been entirely omitted. Among these are studies on brain acetylcholine and gamma-aminobutyric acid metabolism in alcohol-related conditions; the effect of alcohol on brain proteins and nucleotides and the relationship of changes in these to the development of tolerance and physical dependence; and a variety of other areas involving biochemical and physiological parameters. The omission of any of these areas in no way suggests that they are less significant than those that have been covered. It is just that I have attempted to present a cohesive and coherent review of some areas of biological research which thus far appear to throw light on the clinical development and phenomenology of the alcoholism syndrome. In order to present such a thesis, I have inevitably crowded the evidence to fit some of my pet hypotheses. However, in controversial areas (which are many), I have tried to present some of the evidence on both sides and, hopefully, have succeeded in offering a fair overview of the state of the science as it exists today.
 ...
PMID:Biological investigations in alcohol research. 4 96

Although it has not yet been possible to construct a complete model of alcoholism in experimental animals; some aspects of the disease can now be studied with satisfactory laboratory systems. Production of physical dependence requires a period of continuous intoxication; brief intervals of sobriety allow the accrued dependence to disappear. Administration of ethanol by inhalation, with daily injections of pyrazole, allows maintenance of stable blood alcohol levels in mice. In this model, physical dependence arises to its maximum in a week or two and can decay in less than a day. Sedative drugs suppress the mouse withdrawal reactions but drugs that intefere with catecholamine or gamma-aminobutyric acid pathways facilitate withdrawal seizures. Susceptibility to withdrawal seizures is controlled in part by genetic factors.
 ...
PMID:Physical dependence on alcohol in mice. 109 38

In a model of physical dependence in mice, treatment with cyclopyrrolones such as zopiclone and suriclone (from 4 to 400 mg/kg/day), did not modify the sensitivity of the gamma-aminobutyric acid (GABA) receptor complex to the partial inverse agonist FG 7142 following their withdrawal, whereas sensitivity changes were observed after treatment and withdrawal from some benzodiazepines (e.g. lorazepam, diazepam, flunitrazepam and triazolam). These data suggest that, in contrast to some benzodiazepines, zopiclone and suriclone may not produce physical dependence.
 ...
PMID:Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice. 229 Jun 9

Clinical trials have demonstrated that buspirone (BuSpar) is effective in the treatment of anxiety with efficacy and dosage comparable to diazepam or chlorazepate. Buspirone has a unique structure and a pharmacologic profile which distinguishes it from the benzodiazepines. Because it lacks the anticonvulsant, sedative, and muscle-relaxant properties associated with other anxiolytics, buspirone has been termed "anxioselective." Animal studies suggest that it lacks potential for abuse, and this finding is supported by clinical investigations. Further preclinical work supports the contention that buspirone lacks liability to produce physical dependence or to significantly interact with central nervous system depressants such as ethanol. Moreover, biochemical investigations have not identified any direct interaction of buspirone with the benzodiazepine-gamma-aminobutyric acid-chloride ionophore complex. Pharmacologic studies on the molecular level indicate that buspirone interacts with dopamine and serotonin receptors. Recent behavioral, electrophysiological, and biochemical studies have clearly demonstrated that early hypotheses that buspirone might be considered a neuroleptic are no longer tenable. Recent evidence indicates that other neurotransmitter systems (serotonin, norepinephrine, acetylcholine) mediate buspirone's effects. It is hoped that future studies can define the mechanism by which buspirone alleviates the clinical manifestations of anxiety.
 ...
PMID:Pharmacological and clinical effects of buspirone. 286 49

Buspirone is a novel anxiolytic agent unrelated to the benzodiazepines in structure or pharmacologic properties. Extensive clinical studies have shown buspirone to be effective in the treatment of anxiety, with efficacy comparable to diazepam or clorazepate. Buspirone exhibits a unique pharmacologic profile in that it alleviates anxiety without causing sedation or functional impairment and does not promote abuse or physical dependence. Furthermore, preclinical studies have shown that buspirone does not possess anticonvulsant or muscle relaxant properties and does not interact significantly with central nervous system depressants. Biochemical and electrophysiologic studies indicate that buspirone alters monoaminergic and GABAergic systems in a manner different from that of the benzodiazepines. The uniform depressant action of the benzodiazepines upon serotonergic, noradrenergic, and dopaminergic cell firing may result from their facilitatory effect on gamma-aminobutyric acid and its known inhibitory influence in these monoaminergic areas. Unlike the benzodiazepines, buspirone exerts a differential influence upon monoaminergic neuronal activity, suppressing serotonergic activity while enhancing dopaminergic and noradrenergic cell firing. The mechanism of action of buspirone challenges the notion that only one neurotransmitter mediates anxiety. The interaction with multiple neurotransmitters at multiple brain sites suggests that buspirone may alter diverse activities within a "neural matrix of anxiety." In contrast to the benzodiazepines, buspirone orchestrates activity within this neural matrix to achieve effective treatment of anxiety while preserving arousal and attentional processes.
 ...
PMID:Buspirone: review of its pharmacology and current perspectives on its mechanism of action. 287 Jun 39

Two recently developed methods for estimating changes in presynaptic gamma-aminobutyric acid (GABA) homeostasis were used for the first time to evaluate the effects of acute and chronic ethanol treatments on GABA utilization. GABA accumulation in the left substantia nigra zona reticulata (SNR) following unilateral microinjection of gamma-vinyl GABA (GVG; 5 micrograms) was linear for at least 180 min while GABA concentrations in the uninjected right SNR did not change over this period. Net GABA accumulation (left minus right SNR) also increased linearly over this interval. Intraperitoneal (i.p.) administration of ethanol (0.3, 1 or 3 g/kg) 15 min after GVG microinjection did not significantly change either the rate of GABA accumulation in left SNR, the net GABA accumulated or the concentration of GABA in the uninjected right SNR relative to saline injected controls over the 45-min test interval. Likewise, GABA accumulation in the left SNR or steady-state GABA concentrations in the right SNR of chronically intoxicated rats or physically dependent animals withdrawn from ethanol for 12 h did not change significantly from that dextrose-fed controls. In a separate study, the effects of acute and chronic ethanol treatments on the concentration of GABA in synaptosomes isolated from the frontal cortex, hippocampus, tectum, striatum, cerebellum or brainstem were determined. Thirty min after acute treatment with ethanol (0.5, 1, 2 or 4 g/kg, i.p.) the concentration of GABA in synaptosomes from any of these brain regions was not significantly altered. Furthermore, chronic ethanol treatment sufficient to induce physical dependence and a severe ethanol withdrawal syndrome also did not significantly modify synaptosomal GABA concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effect of ethanol on gamma-vinyl GABA-induced GABA accumulation in the substantia nigra and on synaptosomal GABA content in six rat brain regions. 339 59

Clinical trials have indicated that buspirone (Buspar) is effective in the treatment of anxiety with efficacy and dosage comparable to diazepam. Until recently it has been thought that antianxiety drugs must alter benzodiazepine receptor binding in vitro. However, buspirone lacks any structural similarity to te benzodiazepines and does not interact with the benzodiazepine/gamma-aminobutyric acid (GABA) axis. Specifically, buspirone neither stimulates nor inhibits [3H]benzodiazepine binding, does not affect the influence o GABA or halide anions on benzodiazepine binding, and does not interfere with GABA binding or uptake. Behavioral testing has revealed that buspirone does not produce muscle weakness, does not control seizures, does not potentiate the impairment of psychophysiological function or lethality produced by administration of CNS depressants, does not produce sedation/hypnosis and does not appear to possess any abuse potential or liability for physical dependence. Thus, buspirone has been termed an anxioselective agent. Buspirone appears to only interact with the dopaminergic system with reasonable potency and exhibits properties of both a dopamine agonist and a dopamine antagonist. This suggests that dopamine is implicated in the etiology and expression of anxiety. A discussion of this implication is presented with a review of the clinical efficacy of nonbenzodiazepine drugs, especially dopamine agonists and dopamine antagonists, in the management of anxiety. In addition, neuropharmacological studies which have investigated the role of dopamine in animal models of anxiety are considered. Finally, the multiplicity of dopamine receptors and their regional localization in the brain are considered in the formulation of an hypothesis which features a role for the dopaminergic agents in the pharmacotherapy of anxiety.
 ...
PMID:Dopamine and antianxiety activity. 613 25

The benzodiazepine receptor is an allosteric modulatory site present on most, if not all, gamma-aminobutyric acid A (GABAA) receptor channels (GABAA-R). The benzodiazepine receptor recognizes a large spectrum of compounds from different chemical classes that are grouped together as benzodiazepine receptor ligands--of benzodiazepine and non benzodiazepine structure. The GABAA-R is thought to be a heteropentameric protein complex composed of at least three different classes of subunits, with each subunit comprised of up to six structural variants. Binding of GABA to the extracellular domain of the receptor causes a conformational change that opens the channel pore to anions. A classical benzodiazepine achieves a positive allosteric modulation of the GABA channel gating function by increasing the affinity of the receptor for GABA and, possibly, by facilitating the conformational transition from the closed to the open form (benzodiazepine receptor agonists). Inverse agonists of benzodiazepine receptors cause negative allosteric modulation (a decrease in the GABA activity). Benzodiazepine receptor antagonists bind to the benzodiazepine receptor with little effect on GABAA-R functioning. The intrinsic efficacy of benzodiazepine receptor ligands determines the direction and magnitude of allosteric modulation. Benzodiazepine receptor agonists affect neuronal activity in all major neuronal networks. The classical pharmacological profile of benzodiazepine receptor agonists consists of anxiolytic, anticonvulsant, sedative, and myorelaxant activities. Partial agonists of benzodiazepine receptors conserve anxiolytic and anticonvulsant activity, with greatly reduced sedation and muscle relaxation. They promise to present therapeutic advantages, in particular for long term use. In initial studies. they have produced fewer side-effects and showed reduced tolerance development and physical dependence liability.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The multiplicity of actions of benzodiazepine receptor ligands. 830 40

Chronic administration of ethanol in animals leads to CNS tolerance and physical dependence. Subsequent withdrawal of ethanol causes hyperexcitability which is thought to be related to increased sensitivity of N-methyl-D-aspartic acid (NMDA) receptors. The purpose of this study was to investigate sensitivity to NMDA in ethanol-treated animals by detecting damage after intrahippocampal injection of NMDA. Choline acetyltransferase (ChAT) and glutamate decarboxylase (GAD) specific activity was used as markers of cholinergic and gamma-aminobutyric acid neurons, respectively. Ethanol-dependent animals were more liable to die following intrahippocampal injection of either 120 or 240 nmol of NMDA. There was a significantly greater decrease in hippocampal GAD but not ChAT specific activity in the surviving animals. These data support the hypothesis that ethanol dependence is associated with increased sensitivity to NMDA which may be responsible for excitotoxic brain damage and death.
 ...
PMID:Increased sensitivity of the hippocampus in ethanol-dependent rats to toxic effect of N-methyl-D-aspartic acid in vivo. 846 3

A series of imidazo[1,5-a]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies ranging from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [35S]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.
 ...
PMID:High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex. 856 3


1 2 Next >>